tbuckley/cabot-search huggingface dataset:
QOLP-22. DRIVERS OF COST OF SURGERY IN NEWLY-DIAGNOSED GLIOBLASTOMA PATIENTS
Authors: Ankush Chandra, Jacob Young, Cecilia Dalle-Ore, Darryl Lau, Jonathan Rick, Harsh Wadhwa, Mike McDermott, Mitchel Berger, Manish Aghi
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Glioblastoma carries a high economic burden for patients and caregivers. We investigated drivers of hospital costs of surgery for newly-diagnosed glioblastoma. METHODS Retrospective review of GBM patients undergoing first resection at UCSF (2010–2015) and corresponding hospital charges. Our cohort was divided into low (LC) and high cost (HC) groups for total surgical cost. Multivariate regression was used to identify factors driving cost of surgery. RESULTS Of 242 patients, 36.7% (n=86) were females (median age=62 years). The mean total hospital cost for surgery among our patient cohort was $40,384. When comparing the LC and HC groups, mean total hospital cost for surgery for HC patients was almost twice as much as LC group ($51,744 vs $29,023, p&lt; 0.001). Kaplan-Meier analysis revealed that having higher cost of surgery worsened patient prognosis, with a 21% longer overall survival in the LC cohort versus the HC cohort (14.7 vs 17.9 months, p=0.02; HR=1.41 [1.05–1.91], p= 0.023). Tumor diameter at diagnosis was largest for HC group (4.7 cm) versus LC patients (3.9 cm, p=0.002). Multivariate analysis revealed longer hospital stay (F-ratio=8.87; p=0.01), longer ICU stay (F-ratio= 12.34, p&lt; 0.001), younger age at surgery (F-ratio=6.71, p=0.02) and multifocal disease (F-ratio=6.26, p=0.02) to be independent predictors of higher cost of surgery, while having PCP at diagnosis (F-ratio=6.92, p=0.02), health insurance coverage (F-ratio= 4.23, p=0.03) and being married (F-ratio=3.71, p=0.04) were independent predictors of lower cost of surgery. CONCLUSIONS Higher costs of surgery correlate with worse survival outcomes in glioblastoma patients. Beyond the anticipated finding that greater disease burden drives some of this inverse correlation between cost and survival, correctable socioeconomic factors such as PCP and insurance status also drive higher hospital charges for GBM surgery. Manipulation of these factors is necessary to minimize the economic burden of disease and adopt cost-effective surgical treatments for GBM patients.
Molecular Characterization and Novel Therapeutic Strategy for X-Linked Sideroblastic Anemia Associated with ALAS2 Missense Variants
Authors: Koya Ono, Tohru Fujiwara, Kei Saito, Chie Suzuki, Noriyuki Takahashi, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae
Journal: Blood (2019)
Transcriptome Alterations of Isolated Primary Bone Marrow Endothelial Cells Provide Insigt to MGUS and Multiple Myeloma Pathobiology
Authors: Sandro Bräunig, Dimitra Zacharaki, Hongzhe Li, Hooi Ching Lim, Stefan Lang, Thoas Fioretos, Stefan Scheding
Journal: Blood (2019)
Interactome Analysis of APOBEC3B in Multiple Myeloma
Authors: Yasuhiro Kazuma, Kotaro Shirakawa, Anamaria Daniela Sarca, Yoshihito Horisawa, Hirofumi Fukuda, Hiroyuki Matsui, Hiroyuki Yamazaki, Tadahiko Matsumoto, Fumiko Tanabe, Ryo Morishita, Shinji Ito, Akifumi Takaori-Kondo
Journal: Blood (2019)
Abstract 12619: Short-Term Effects of Statin Therapy on Major Adverse Cardiovascular Events in Stable Symptomatic Patients Stratified by Baseline Coronary Artery Calcium Score
Authors: Santanu Biswas, Stacey Knight, Viet T Le, David B Min, Kent G Meredith, C M Minder, Donald L Lappé, Joseph B Muhlestein, Jeffrey L Anderson, Kirk U Knowlton
Journal: Circulation (2018)

Introduction: Statin therapy has been shown to reduce future major adverse cardiovascular events (MACE) in secondary prevention patients and select patients in primary prevention. The coronary arte...
Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
Authors: Satyajit Kosuri, Sang Mee Lee, Hongtao Liu, Mylove Mortel, Lucy A Godley, Richard A. Larson, Olatoyosi Odenike, Wendy Stock, Justin Kline, Peter A. Riedell, Koen Van Besien, Michael R. Bishop, Andrew S. Artz
Journal: Blood (2019)
Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial
Authors: Odelia Amit, Yael Bar-On, Galit Perets, Lena Atlas, Liat Shargian, Moshe Yeshurun, Bruria Yachini, Chen Karni, Ron Ram
Journal: Blood (2019)
Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Multiple Myeloma and Stratification of Revised International Staging System Stage II
Authors: Toshiki Terao, Yoichi Machida, Takafumi Tsushima, Akihiro Kitadate, Daisuke Miura, Kentaro Narita, Masami Takeuchi, Kosei Matsue
Journal: Blood (2019)
Health problems of anaesthetists and their families.
Authors: M Vowles, R J Pethybridge, F Brimblecombe
Journal: BMJ (1979)

validity because of differences of definition.Internal comparison between the "exposed" and control infants in Dr Tomlin's survey shows no overall significant difference in malformation rates (26 of 277 v 4 of 92, X(2)= 1-72, P-0-2).In summary, Dr Tomlin's survey, while provocative, adds little that is concrete to the existing literature on the possible relationship between exposure to anaesthetic agents and outcome of pregnancy.
Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation
Authors: Julia Driessen, Gerben J.C. Zwezerijnen, Jakoba J Eertink, Marie José Kersten, Anton Hagenbeek, Otto S Hoekstra, Josée M Zijlstra, Ronald Boellaard
Journal: Blood (2019)
Management of Crohn’s disease: summary of updated NICE guidance
Authors: Rui Martins, Chris Carmona, Bruce George, Jenny Epstein
Journal: BMJ (2019)

### What you need to know

Crohn’s disease is a chronic inflammatory disease that mainly affects the gastrointestinal tract. Approximately 115 000 people are living with Crohn’s in the UK. There is no known cure, so the aim of medical treatment is to induce or maintain absence of symptoms (remission). If symptoms are refractory to medication, surgical resection may be required. Post-surgical recurrence is common, with approximately 20-40% of patients requiring reoperation within 10 years.12

This article summarises recent recommendations from the update of the National Institute for Health and Care Excellence (NICE) guideline for the management of Crohn’s disease in children, young people, and adults.3 The focus of this update is on maintaining remission in people with Crohn’s disease after surgery. It does not cover people who have had surgery and are not in remission—for example, people who have active disease at other sites.

All other areas of the guideline, such as induction of remission and surgery, remain …
Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003
Authors: Rachael E Hough, Amy A Kirkwood, Sujith Samarasinghe, Clare J Rowntree, Nicholas John Goulden, Ajay Vora
Journal: Blood (2019)
A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients
Authors: Paraskevi Karousi, Aristea-Maria Papanota, Pinelopi I Artemaki, Christine Liacos, Christos K. Kontos, Dimitris Patseas, Aikaterini-Anna Liosi, Nefeli Mavrianou-Koutsoukou, Maria-Anna Kalioraki, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Panagiotis Malandrakis, Maria Gavriatopoulou, Eftathios Kastritis, Evangelos Terpos, Andreas Scorilas, Meletios A. Dimopoulos
Journal: Blood (2019)
Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial
Authors: Martin Dreyling, Marco Ladetto, Jeanette K. Doorduijn, Eva Gine, Mats Jerkeman, Ulrich Mey, Michal Szymczyk, Martin Hutchings, Arne Kolstad, Gregor Verhoef, Marek Trneny, Maria Gomes da Silva, Christiane Pott, Wolfram Klapper, Michael Unterhalt, Eva Hoster
Journal: Blood (2019)
To Assess the Appropriateness of the Venous Thromboembolism (VTE) Prophylaxis Agent Used Based on the VTE Risk Stratification in Hospitalised Acutely Ill Medical Patients
Authors: Maitreyee Rai, Jian Liang Tan, Meghana Parsi, Malvika Duphare, Mylene S. Go
Journal: Blood (2019)
Lncrnas As New Partners of Novel Chimeric Transcripts in Multiple Myeloma
Authors: Ane Amundarain, Luis Vitores Valcárcel, Raquel Ordoñez, Leire Garate, Estíbaliz Miranda, Xabier Cendoya, Maria Jose Calasanz, Bruno Paiva, Jesús San-Miguel, Francisco J Planes, Felipe Prósper, Xabier Agirre
Journal: Blood (2019)
NCOG-04. COGNITIVE FUNCTIONS BEFORE RADIOTHERAPY IN PEDIATRIC PATIENTS WITH BRAIN TUMORS
Authors: Juan Li, Linbo Cai, Mingyao Lai, Qingjun Hu
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE To assess the cognitive functions before radiotherapy in pediatric patients with brain tumors and explore the related influence factors. METHODS Before radiotherapy for brain tumors, adaptive behavior scale (adaptive quotient) and Wechsler intelligence scale for children were used to evaluate the cognitive functions in pediatric patients. Herein the assessment items of verbal IQ, performance IQ, total score and the corresponding percentile. The cognitive functions of pediatric patients with different pathological diagnoses, lesion locations, with or without epilepsy, hydrocephalus or hypopituitarism were compared. RESULTS A total of 128 pediatric patients were enrolled in this study. The mean verbal IQ score was 83.7±20.8 (range, 36–128), and the corresponding percentile mean value was 27.699±30.3. The mean performance IQ score was 82.83±20.5 (range, 30–126), and the corresponding percentile mean value was 26.6±29.1. The total score of Wechsler intelligence scale was 0–128, with a mean value of 81.4±21.7, and the corresponding percentile was 0–97, with a mean value of 25.5±28.5. Moreover, the adaptive quotient for all enrolled patients was 32–164, with a mean value of 95.1±29.4. The results of multivariate analysis on the clinical factors related to cognitive functions revealed that the mean performance IQ, the corresponding percentile and the mean of the total score of Wechsler intelligence scale in patients with lesions involving basal ganglia region were 76±16, 15.1±19.6 and 75.29±15, respectively, which were lower than 84±20.7, 28±19.1 and 82.4±22 in those with lesion without involving basal ganglia region, with statistical differences (P= 0.031, 0.018, 0.046). CONCLUSION The cognitive functions before radiotherapy in pediatric patients with brain tumors are proved to be inferior to those in normal children. The performance IQ and total score of pediatric patients with brain tumors involving basal ganglia region were lower than those of the other patients for the lesions have affected the limb movement.
Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics
Authors: Francesco Mannelli, Sara Bencini, Benedetta Peruzzi, Paola Guglielmelli, Annalisa Pacilli, Giada Rotunno, Francesca Gesullo, Blerina Jance, Marida Bonetti, Roberto Caporale, Francesco Annunziato, Alessandro M. Vannucchi
Journal: Blood (2019)
Pharmacologic Inhibition of SUMO-Activating Enzyme (SAE) with TAK-981 Augments Interferon Signaling and Regulates T Cell Differentiation in Ex Vivo studies of Chronic Lymphocytic Leukemia (CLL)
Authors: Vi Lam, Scott R Best, Nur Bruss, Tingting Liu, Taylor Hashiguchi Rowland, Dennis Huszar, Alexey Danilov
Journal: Blood (2019)
Genito-Urinary and Venereal Diseases.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Significant Features of DNA Methylation at Bivalent Promotor and Repressed Polycomb Regions in Pediatric AML-the Jccg Study, JPLSG AML-05-
Authors: Genki Yamato, Tomoko Kawai, Norio Shiba, Yusuke Hara, Kentaro Ohki, Taeko Kaburagi, Kenichi Yoshida, Yuichi Shiraishi, Satoru Miyano, Nobutaka Kiyokawa, Daisuke Tomizawa, Akira Shimada, Manabu Sotomatsu, Hirokazu Arakawa, Souichi Adachi, Takashi Taga, Keizo Horibe, Seishi Ogawa, Kenichiro Hata, Yasuhide Hayashi
Journal: Blood (2019)
Old People and Mental Hospitals
Authors: R. J. Hetherington
Journal: BMJ (1965)

BRiTisH 879 but when assessing symptoms that are by definition subjective the patients' opinions are of importance.'Whether or not symptomatic improvement correlates with objective measurements is another matter.It would appear to be particularly important to consider patients' opinions in fluctua- ting conditions such as bronchospasm, where they may well be able to give an overall im- pression of their clinical condition during a period of time, while isolated objective tests only give information on a few minutes separated by many weeks.Another example occurred in the same issue of the B.M.7. in a review of inhaled steroids for asthma (" Any Questions ?" 18 September, p. 691).Admittedly the trials quoted differed in many ways, but the studies relying mainly on subjective assessments2-5 found that inhalations of hydrocortisone acetate were significantly better than placebo while trials utilizing isolated lung function tests'7 were unable to demonstrate a difference between the two regimens.In the trial of breathing exercises it is possible that cough and sputum were worse in the treated group owing to the higher incidence of colds (58% as opposed to 40%), and that the patients took this into considera- tion when they declared an overall improve- ment in the symptom of dyspnoea after breathing exercises.It was, of course, impossible to conduct a double-blind trial on breathing exercises, and Stewart and Anderson8 are probably quite correct in stating that such exercises produce little or no benefit and that apparent im- provement was due to gratitude for extra attention.Nevertheless, it is worth mentioning that in trials of this sort where assessments of subjective symptoms are made over a prolonged period due weight should be given to patients' opinions, as isolated objective tests have considerable limitations.-Iam, etc.,
NCOG-07. COGNITIVE SEQUELAE OF RADIOTHERAPY IN LOW-GRADE GLIOMA PATIENTS 26 YEARS AFTER INITIAL DIAGNOSIS: FINAL REPORT
Authors: Patricia WM den Otter, Linda MC Lorenz, Jaap C Reijneveld, Philip C de Witt Hamer, Martin Taphoorn, Mathilde CM Kouwenhoven, Tom Snijders, Süan T Lie, Linda Douw, Martin Klein
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Our previous study among 195 low-grade glioma (LGG) patients six years after initial diagnosis, showed that high radiation doses (&gt;2 Gy) were associated with neurocognitive disability. Follow-up at 12 years in 64 LGG patients showed patients without radiotherapy to have stable neurocognitive and radiological status while attentional functioning deteriorated between 6 and 12 years in irradiated patients. The present assessment at a mean of 26 years after initial diagnosis and treatment, investigates the neurocognitive sequelae of radiotherapy in long-term survivors. METHODS Patients who were alive since the 12 year follow-up were invited for assessment of the same neurocognitive domains as tested at 6 and 12 years: attention, executive functioning, verbal memory, working memory, psychomotor functioning, and information processing speed. Using a mixed model, standardized scores of neurocognitive performance were compared between treatment (radiotherapy versus no radiotherapy) and over time. FINDINGS: 32 patients, of whom 13 (41%) had received radiotherapy, completed the assessment at a mean of 26 years (range 20–35 years) after initial diagnosis. Patients who had radiotherapy had more attentional deficits at the present assessment, than those who did not (–1·0 [SD 1·6] vs 0·33 [0·65], p=0·01; mean difference 1·3, 95% CI 0·3–2·3). Furthermore, patients who had radiotherapy had reduced attentional functioning over time (p=0·03), regardless of antiepileptic drug use. Three (23%) patients who had radiotherapy developed neurocognitive disabilities deficits in at least four of the 20 neuropsychological test parameters compared with five (26%) patients who did not have radiotherapy. INTERPRETATION: Extreme long-term, and probably surviving LGG patients who had radiotherapy show relatively stable and adequate neurocognitive functioning when compared to patients who did not have radiotherapy. Apart from attentional functioning, no progression of neurocognitive deficits at 26 years after initial diagnosis were found.
Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib
Authors: Cheryl A Cohler Peretz, Lisa H F McGary, Tanya F Kumar, J Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, Chunxiao Zhang, Mark J. Levis, Alexander E. Perl, Anskar Yu Hung Leung, Catherine C. Smith
Journal: Blood (2019)
High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma
Authors: Pamela S. Becker, Kim Quach, Ted A Gooley, Edward N. Libby, Andrew J. Cowan, David G. Coffey, Bret Gary Degraaff, Cody Hammer, Jin Dai, Sylvia Chien, Josh Epworth, Gabrielle A Zecha, Heather Smith, Timothy S Martins
Journal: Blood (2019)
Whither TMS: A One-Trick Pony or the Beginning of a Neuroscientific Revolution?
Authors: Mark S. George
Journal: American Journal of Psychiatry (2019)

Psychiatry has been at the forefront of advancing clinical transcranial magnetic stimulation (TMS) since the mid-1990s, shortly after the invention of modern TMS in 1985 by Barker. Clinical TMS for psychiatric applications is advancing rapidly, with novel methods and innovations for treating depression, as well as a new clinical indication in obsessive-compulsive disorder. This review summarizes the recent findings and peers into the near future of this fertile and rapidly changing field. It is possible that many, perhaps even most, psychiatrists will be incorporating some form of brain stimulation into their practice within the next decade. The author summarizes the reasons for this optimistic view.
Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients
Authors: Jingjing Shang, Weiqin Yao, Lingzhi Yan, Xiaolan Shi, Ruju Wang, Shuang Yan, Yong Liu, Depei Wu, Fu Cheng Cheng
Journal: Blood (2019)
Very High Seroprevalence of CMV and EBV Among a Large Series of Patients with Hematological Malignancies at a Tertiary Care Center in Saudi Arabia - a Case for Investigating Cooperativity of Viruses in Carcinogenesis?
Authors: Abdul Rehman Z. Zaidi, Maged O. Al-Ammari, Mohammed AlNoamani, Syed Y. Altaf, Nawal AlShehry, Imran K. Tailor, Ibraheem H. Motabi, Mubarak S. AlGhamdi, Syed Ziauddin A. Zaidi
Journal: Blood (2019)
O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response
Authors: J. Brahmer, L. Horn, B. Hossein, S. Ramalingam, A. Pluzanski, M.A. Burgio, M.C. Garassino, L.Q.M. Chow, S. Gettinger, L. Crino, D. Planchard, C. Butts, A. Drilon, J. Wojcik-Tomaszewska, G. Otterson, S. Agrawal, A. Li, J.R. Penrod, S.J. Antonia, Y. Bautista
Journal: Journal of Thoracic Oncology (2019)
A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
Authors: Richard E. Champlin, Uday Popat, Betul Oran, Stefan O. Ciurea, Partow Kebriaei, Amin M. Alousi, Gheath Alatrash, Qaiser Bashir, Issa F. Khouri, Chitra Hosing, Paolo Anderlini, Roy B Jones, David Marin, Rohtesh Mehta, Yago Nieto, Amanda L. Olson, Muzaffar H. Qazilbash, Katy Rezvani, Elizabeth J. Shpall, Julianne Chen, Gabriela Rondon, Becky McMullin, Vivian P Al Jahdhami, Jitesh Kawedia, Benigno C. Valdez, Junsheng Ma, Peter F Thall, Borje S Andersson
Journal: Blood (2019)
Expression of ERCC1 protein (excision repair cross complementing group 1) in patients with invasive carcinoma of the uterine cervix (CC) undergoing definitive chemoradiation (CR).
Authors: Inacelli Queiroz de Souza Caires, Rafael Caires-Lima, Renata Colombo, Clarissa CA Ramos, Karime Kalil Machado, Sheila Aparecida Coelho Siqueira, Heloisa de Andrade Carvalho, Julia Tizue Fukushima, Thais Rodrigues Adra, Paulo M. Hoff, Maria Del Pilar Estevez-Diz
Journal: Journal of Clinical Oncology (2012)

e15562 Background: CC is the leading cause of cancer death among women in developing countries. ERCC1 protein participates in DNA repair through the nucleotide excision repair pathway, involved in resistance to platinum-based chemotherapy. Its value as a predictive marker of tumor response to treatment, progression or death is still unknown. We evaluated ERCC1 protein expression and clinical variables as a predictive marker of progression-free survival (PFS) and overall survival (OS) in patients (pts) with CC submitted to CR. Methods: Retrospective data analysis of pts with histological diagnosis of CC, treated with CR between 2004-2009. Platinum-based chemotherapy was administered weekly (x6) concurrent to external beam radiotherapy (EBRT) to the pelvis (39.6 – 45.0 Gy), parametrial boost (14.0 – 20.0 Gy) when indicated and high-dose rate brachytherapy (HDR) (28.0 – 30.0 Gy). ERCC1 expression was assessed by immunohistochemistry (IHC). Results: We analyzed 75 pts, median age was 55 years (range 24-76), the performance status (PS) was 0 or 1 at baseline in 50 pts (66%) and 63 had squamous histology (84%). Thirty-two were stage IIB (43%) and 19 were IIIB (25%). Sixty-five patients received cisplatin 40mg/m 2 /w (87%) and 9, carboplatin AUC2/w (12%), median of 6 cycles (range 2-9). Median RT and HDR doses were 59.4 Gy (range 40.4 to 60.3) and 28.0 Gy (range 14.0 – 37.5), respectively. Thirty-two pts were available by ERCC1 IHC and all expressed the marker. Median PFS and OS were 35.5 (95% CI – 13.8 - 57.6) and 81 (95% CI- 21.2 - 140.8) months, respectively. In multivariate analysis, receiving &lt; 6 chemotherapy cycles and baseline Hb &lt;10.0 were correlated with disease progression and death, HR 0.302; p 0.011 (95% CI- 0.012-0.762) and HR 0.6; p 0.00 (95% CI- 0.474 – 0.760), respectively. PS at baseline did not correlate with PFS or OS, HR 0.985; p 0.614 (95% CI 0.930 – 1.044). Conclusions: In this population, since all pts expressed the protein, ERCC1 expression couldn't discriminate patients who most benefit from CR. Interestingly, a minimum of 6 chemotherapy cycles and a baseline Hb ≥ 10.0 seem to have a prognostic value.